Report Overview

Vaso occlusive crisis is the most common clinical manifestation of sickle cell disease. It is responsible for a significant volume of hospitalizations and emergency department visits by the affected patients. Recent studies suggest that nearly half of the people suffering from sickle cell disease experience vaso occlusive crisis, with some patients having 6 or more such episodes every year. Repeated episodes can lead to severe health complications and thus, there is a heightened impetus to develop effective drugs to alleviate the condition.

  • Major companies involved in the vaso occlusive crisis pipeline drugs market include AstraZeneca, Novartis Pharmaceuticals, Hoffmann-La Roche, and Pfizer.
  • Leading drugs currently under pipeline include sufentanil, crizanlizumab, and inclacumab among others.
  • The advancement in targeted therapies, such as monoclonal antibodies targeting P-selectin, is playing a significant role in the development of vaso occlusive drug pipeline and is showing promising results in clinical trials to reduce vaso occlusive crisis frequency.

Report Coverage

The Vaso Occlusive Crisis Drug Pipeline Insight Report by Expert Market Research gives comprehensive insights into vaso occlusive crisis drugs currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for vaso occlusive crisis. The report includes the analysis of over 100 pipeline drugs and 50+ companies. The vaso occlusive crisis pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from vaso occlusive crisis.

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to vaso occlusive crisis.

Vaso Occlusive Crisis Drug Pipeline Outlook

A vaso occlusive crisis, or VOC, refers to a condition when sickled red blood cells block the flow of blood to the extent that the tissues experience oxygen deprivation. This triggers an inflammatory response that leads to substantial pain which primarily occurs in the chest, back, or extremities. Besides causing acute pain, a vaso occlusive event can make the patient prone to various health issues such as strokes, arthritis, and kidney failure.

For the acute management of vaso occlusive crisis, opioids are commonly given to the patient for pain relief. Hydroxyurea, an antimetabolite chemotherapeutic agent, is also widely used to prevent painful crises in sickle cell anemia patients. In recent years, Adakveo (crizanlizumab) and Endari (L-glutamine) were cleared by the US Food and Drug Administration (FDA) as vaso occlusive crisis-preventing therapies. Furthermore, in December 2023, a major milestone was achieved with the FDA approval of the first-ever cell-based gene therapy based on CRISPR/Cas9, Casgevy, for the treatment of sickle cell disease patients aged 12 years and above with recurrent vaso-occlusive crises. The rise in the development and regulatory approval of novel gene therapies are among the major trends, impacting the drug pipeline outlook positively.

Vaso Occlusive Crisis – Drug Pipeline Therapeutic Assessment

This section of the report covers the analysis of vaso occlusive crisis drugs based on several segmentations including:

By Phase

  • Late-Stage Products (Phase 3 and Phase 4) 
  • Mid-Stage Products (Phase 2) 
  • Early-Stage Products (Phase I) 
  • Preclinical and Discovery Stage Products  

By Drug Class

  • Corticosteroids
  • Immunosuppressive Agents
  • Intravenous Immunoglobulins (IVIG)
  • Cytotoxic Agents
  • Monoclonal Antibodies

By Route of Administration

  • Oral
  • Parenteral
  • Others

Vaso Occlusive Crisis – Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II covers a major share of the total clinical trials for vaso occlusive crisis. There are around 31 drugs in phase II for vaso occlusive crisis.

Vaso Occlusive Crisis – Pipeline Assessment Segmentation, By Drug Classes

The drug molecules categories covered under vaso occlusive crisis pipeline analysis include analgesics, anti-sickling agents, monoclonal antibodies, amino acid supplements, and gene therapy. These drugs are prescribed according to the symptoms and the underlying cause of vaso occlusive crisis.

Vaso Occlusive Crisis Clinical Trials Therapeutic Assessment – Competitive Dynamics

The EMR report for the vaso occlusive crisis drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in vaso occlusive crisis clinical trials:

  • AstraZeneca
  • Novartis Pharmaceuticals
  • Hoffmann-La Roche
  • Pfizer
  • Asklepion Pharmaceuticals, LLC
  • Mast Therapeutics, Inc.
  • GlycoMimetics Incorporated
  • Anthera Pharmaceuticals
  • Reprixys Pharmaceutical Corporation
  • Beam Therapeutics Inc.

Vaso Occlusive Crisis – Emerging Drugs Profile

Major drugs currently in the drug pipeline are as follows:

Crovalimab

Sponsored by Hoffmann-La Roche, the drug is being investigated as an adjunct treatment to help prevent vaso-occlusive episodes (VOE) in sickle cell disease. The study is being conducted at 41 locations including the United States and Brazil.

Inclacumab

The Phase 3 study, involving inclacumab (a P-selectin inhibitor), is sponsored by Pfizer. The safety and effic...

Sufentanil

Sufentanil is an opioid analgesic, currently in Phase III clinical development. The INVOPE trial will evaluate...

Crizanlizumab

Crizanlizumab is a monoclonal antibody medication, used to reduce the frequency of vaso-occlusive crises. Nova...

Reasons To Buy This Report

The Vaso Occlusive Crisis Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for vaso occlusive crisis. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within vaso occlusive crisis pipeline insights.

Key Questions Answered in the Vaso Occlusive Crisis – Pipeline Insight Report

  • What is the current landscape of vaso occlusive crisis pipeline drugs?
  • How many companies are developing vaso occlusive crisis drugs?
  • How many phase III and phase IV drugs are currently present in vaso occlusive crisis pipeline drugs?
  • Which companies/institutions are leading the vaso occlusive crisis drug development?
  • What is the efficacy and safety profile of vaso occlusive crisis pipeline drugs?
  • What are the opportunities and challenges present in the vaso occlusive crisis drug pipeline landscape?
  • Which company is conducting major trials for vaso occlusive crisis drugs?
  • What major geographies are covered for vaso occlusive crisis clinical trials?
  • What are emerging trends in vaso occlusive crisis clinical trials?

Related Reports

Global Sickle Cell Disease Treatment Market

Global Clinical Trials Market

*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*

Looking for specific insights?

Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!

Report Summary

Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.

Key Highlights of the Report

Please note that the figures mentioned in the description serve as estimates and may vary from the actual figures presented in the final report.

Scope of the Report

Details

Drug Pipeline by Clinical Trial Phase?

  • Late-Stage Products (Phase III and Phase IV)
  • Mid-Stage Products (Phase II)
  • Early-Stage Products (Phase I)
  • Preclinical and Discovery Stage Products

Route of Administration?

  • Oral
  • Parenteral
  • Others

Drug Classes?

  • Analgesics
  • Anti-sickling Agents
  • Monoclonal Antibodies
  • Amino Acid Supplements
  • Gene Therapy

Leading Sponsors Covered?

  • AstraZeneca
  • Novartis Pharmaceuticals
  • Hoffmann-La Roche
  • Pfizer
  • Asklepion Pharmaceuticals, LLC
  • Mast Therapeutics, Inc.
  • GlycoMimetics Incorporated
  • Anthera Pharmaceuticals
  • Reprixys Pharmaceutical Corporation
  • Beam Therapeutics Inc.

Geographies Covered?

  • North America
  • Europe
  • Asia Pacific
  • Others

Purchase Full Report

Datasheet

 

USD 1,999

tax inclusive*

  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

One User

USD 2,499

tax inclusive*

  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Five User License

Five Users

USD 3,499

tax inclusive*

  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

Unlimited Users

USD 4,499

tax inclusive*

  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

How To Order

Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.

Select License Type

Choose the right license for your needs and access rights.

Click on ‘Buy Now’

Add the report to your cart with one click and proceed to register.

Select Mode of Payment

Choose a payment option for a secure checkout. You will be redirected accordingly.

Strategic Solutions for Informed Decision-Making

Connect For More Information

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.

Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.

We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.

Back to top

We’re here to help answer any questions about our products and services.

Contact us

Locations


United States (Head Office)

30 North Gould Street, Sheridan, WY 82801

+1-415-325-5166

Australia

63 Fiona Drive, Tamworth, NSW

+61 448 06 17 27

India

C130 Sector 2 Noida, Uttar Pradesh 201301

+91-858-608-1494

Philippines

40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.

+63 287899028, +63 967 048 3306

United Kingdom

6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London

+44-753-713-2163

Vietnam

193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City

+84865399124